Detalhe da pesquisa
1.
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients.
Eur J Nucl Med Mol Imaging
; 49(11): 3830-3840, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35451612
2.
Pituitary Function after High-Dose 177Lu-DOTATATE Therapy and Long-Term Follow-Up.
Neuroendocrinology
; 111(4): 344-353, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32259830
3.
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.
Eur J Nucl Med Mol Imaging
; 44(9): 1480-1489, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28331954
4.
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE.
J Nucl Med
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38724277
5.
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Lancet Oncol
; 13(9): 897-905, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22898678
6.
Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with (177)Lu- and (90)Y-BR96 mAbs.
Med Phys
; 39(7): 4434-43, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22830776
7.
Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177Lu-DOTATATE.
J Nucl Med
; 63(3): 399-405, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34272319
8.
Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres.
Endocrine
; 75(3): 856-864, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34859391
9.
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).
J Clin Oncol
; 40(17): 1870-1878, 2022 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35192411
10.
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.
Eur J Nucl Med Mol Imaging
; 38(7): 1393-406, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21494856
11.
Different toxicity profiles for drug- versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model.
Acta Oncol
; 50(5): 711-8, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21214493
12.
Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines.
Acta Otolaryngol
; 140(4): 337-343, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31922436
13.
High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
Biol Blood Marrow Transplant
; 15(9): 1077-85, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19660720
14.
[Fellowship success story in Lund]. / Fellowship framgångssaga i Lund
Lakartidningen
; 111(41): 1787, 2014.
Artigo
em Sueco
| MEDLINE | ID: mdl-25699327
15.
The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves' Disease.
Eur Thyroid J
; 8(2): 64-69, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31192144
16.
Improved tumor targeting and decreased normal tissue accumulation through extracorporeal affinity adsorption in a two-step pretargeting strategy.
Clin Cancer Res
; 13(18 Pt 2): 5572s-5576s, 2007 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17875791
17.
Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy.
EJNMMI Phys
; 5(1): 12, 2018 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29974391
18.
Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion.
J Nucl Med
; 48(2): 269-76, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17268025
19.
Clinical applications of newer radionuclide therapies.
Eur J Cancer
; 42(8): 994-1003, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16564689
20.
Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
Clin Cancer Res
; 11(14): 5215-22, 2005 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16033839